Truvian Sciences Raises $105M Series C To Fund Development Of Point-Of-Care Testing Platform
Truvian Sciences will use the proceeds to fund regulatory submission for its POC testing system in Europe and the US with hopes to bring to retailers, pharmacies, health systems in 2022.
You may also be interested in...
Medtech Insight talked with Lux Capital’s general partner Deena Shakir about her investments in women’s health, untapped opportunities and barriers, gender equality in investment, and her outlook for investment in women’s health.
After years of underfunding, stigmatization and lack of research, companies working on products and services that address women’s health care are gaining traction. But the sector also faces unique challenges, such as gaining approval for ads on major social media platforms.
Minute Insight: Abbott Wins Expanded FDA Approval For Proclaim XR Spinal Cord Stimulator For Diabetic Peripheral Neuropathy
Abbott said a major competitive benefit of the Proclaim XR SCS system is the battery life of up to 10 years at low settings.